Skip to main content
Premium Trial:

Request an Annual Quote

JP Morgan Initiates Coverage of Oxford Nanopore Technologies With Overweight Rating

NEW YORK – JP Morgan on Wednesday initiated coverage of Oxford Nanopore Technologies, giving the company's shares an Overweight rating and a June 2023 price target of 725 pence ($9.78).

In a note to investors, analyst James Gordon wrote that Oxford Nanopore is a "differentiated player, operating in an attractive segment, with a very strong long-term top-line growth outlook."

But key risks include competition from established sequencing competitors, potential nanopore-based competition, pressure from falling DNA sequencing prices, and failure to achieve timely profitability.

The UK-based nanopore sequencing firm went public on the London Stock Exchange in September, raising £330.1 million ($445.1 million) and valuing the company at approximately £4.80 billion.

Gordon said he sees the DNA sequencing market doubling to approximately $8 billion by 2025 and expects Oxford Nanopore to "outperform the already strong growth of the DNA sequencing market." The company could achieve break-even in 2025, he added.

In Wednesday trading on the London Stock Exchange, shares of Oxford Nanopore were flat at 591.5 pence.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.